Who is sponsoring NCT06772974?

NCT06772974 is sponsored by Nawaz Sharif Medical College.

What drugs are being tested in NCT06772974?

Interventions in NCT06772974: Doxylamine Succinate USP, Ginger.

What condition does NCT06772974 study?

NCT06772974 studies Nausea Gravidarum, Hyperemesis Gravidarum.

Is NCT06772974 still recruiting?

NCT06772974 is currently not yet recruiting. Last updated 17 January 2025.

Last reviewed 2025-01-17 · How we verify

NCT06772974: GDNVP

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Tablet Ginger Versus Tablet Doxylamine Succinate in Control of Nausea and Vomiting in Pregnancy

Not yet recruiting NA Last updated 17 January 2025

What this trial tests

NA trial testing Doxylamine Succinate USP in Nausea Gravidarum in 66 participants. Not yet recruiting.

Timeline

15 January 2025

Primary endpoint
30 June 2025

15 July 2025

Quick facts

Lead sponsor	Nawaz Sharif Medical College
Phase	NA
Status	Not yet recruiting
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	66
Start date	15 January 2025
Primary completion	30 June 2025
Estimated completion	15 July 2025
Sites	1 location across Pakistan

Drugs / interventions tested

Doxylamine Succinate USP — full drug profile →
Ginger — full drug profile →

Conditions studied

Nausea Gravidarum — all drugs for Nausea Gravidarum →
Hyperemesis Gravidarum — all drugs for Hyperemesis Gravidarum →

Sponsor

Nawaz Sharif Medical College

Who can join

Adults 18 to 49, female only, with Nausea Gravidarum or Hyperemesis Gravidarum. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Nausea and vomiting are common GI symptoms of pregnancy. Multiple managing options have been used for NVP. Doxylamine succinate is used as first line treatment for NVP despite that alternative modalities such as ginger extracts and tablets is being explored. This RCT will be conducted after taking ethical approval and informed consent, in Department of Gynecology, Aziz Bhatti Shaheed teaching hospital, Gujrat. Patients will be divided into two equal groups. One group will receive tablet ginger while other group will receive Doxylamine succinate tablets. Baseline PUQE score (3- 15 point scale) over 24 hour will be noted according to symptoms of nausea and vomiting following 7 days of treatment and then at 2nd and 3rd week. Comparison of the change in the severity of nausea from baseline scores (Post-therapy PUQE score - base line scores) in both groups will be considered for results.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06772974 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Nawaz Sharif Medical College
Last refreshed: 17 January 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06772974.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing